Literature DB >> 12011956

Clinical profile, predictors of mortality, and treatment of patients after myocardial infarction, in an academic medical center hospital.

Leonardo A M Zornoff1, Sérgio A R Paiva, Vanessa M Assalin, Patrícia M S Pola, Luís E Becker, Marina P Okoshi, Luiz S Matsubara, Roberto M T Inoue, Joel Spadaro.   

Abstract

OBJECTIVE: To evaluate clinical profiles, predictors of 30-day mortality, and the adherence to international recommendations for the treatment of myocardial infarction in an academic medical center hospital.
METHODS: We retrospectively studied 172 patients with acute myocardial infarction, admitted in the intensive care unit from January 1992 to December 1997.
RESULTS: Most patients were male (68%), white (97%), and over 60 years old (59%). The main risk factor for coronary atherosclerotic disease was systemic blood hypertension (63%). Among all the variables studied, reperfusion therapy, smoking, hypertension, cardiogenic shock, and age were the predictors of 30-day mortality. Most commonly used medications were: acetylsalicylic acid (71%), nitrates (61%), diuretics (51%), angiotensin-converting enzyme inhibitors (46%), thrombolytic therapy (39%), and beta-blockers (35%).
CONCLUSION: The absence of reperfusion therapy, smoking status, hypertension, cardiogenic shock, and advanced age are predictors of 30-day mortality in patients with acute myocardial infarction. In addition, some medications that are undoubtedly beneficial have been under-used after acute myocardial infarction.

Entities:  

Mesh:

Year:  2002        PMID: 12011956     DOI: 10.1590/s0066-782x2002000400007

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  1 in total

1.  Multi-state analysis of hypertension and mortality: application of semi-Markov model in a longitudinal cohort study.

Authors:  Azra Ramezankhani; Michael J Blaha; Mohammad Hassan Mirbolouk; Fereidoun Azizi; Farzad Hadaegh
Journal:  BMC Cardiovasc Disord       Date:  2020-07-06       Impact factor: 2.298

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.